Bausch + Lomb Q2 revenue $1.278B, GAAP loss narrows to $62M, raises FY2025 guide

Bausch & Lomb Corp

2025-Q2 EPS reported -$0.78 revenue$2,415,000,000

Revenue $1.278B, +5% as reported (+3% constant currency); Vision Care +8%, Surgical +3%, Pharma flat.
GAAP net loss $62M ($0.18 loss per share) vs $151M loss ($0.43) a year ago; adjusted net income $25M ($0.07 adjusted EPS).
Adjusted EBITDA $191M vs $209M prior year; Adj EBITDA ex-IPR&D $192M vs $212M.
Raised FY2025 guidance: revenue $5.05B-$5.15B (prior $5.0B-$5.1B), constant currency growth ~5-7%; Adj EBITDA ex-IPR&D $860M-$910M.
Resumed full production of enVista IOLs following recall; dry eye portfolio reached ~$1B trailing revenue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.